Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 13/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL849185 | 1.00 | PTGER2 (0.38) | PTGER2PTGDRPTGER3DUTALDH1A1 | |
| SCHEMBL16302378 | 0.92 | PTGER2 (0.39) | PTGER2PTGDRPTGER3DUTHDAC1 | |
| SCHEMBL848123 | 0.90 | PTGER2 (0.36) | PTGER2PTGDRPTGER3DUTALDH1A1 | |
| SCHEMBL850848 | 0.90 | PTGER2 (0.36) | PTGER2PTGDRPTGER3DUTALDH1A1 | |
| SCHEMBL13555131 | 0.81 | PTGER2 (0.37) | PTGER2PTGDRPTGER3ALDH1A1POLB | |
| SCHEMBL16302337 | 0.79 | PTGER2 (0.36) | PTGER2PTGDRPTGER3DUTHDAC1 | |
| SCHEMBL850484 | 0.74 | ALDH1A1 (0.36) | PTGER2PTGDRPTGER3ALDH1A1POLB | |
| SCHEMBL879707 | 0.73 | TSHR (0.41) | PTGER2PTGDRPTGER3ALDH1A1POLB | |
| SCHEMBL850670 | 0.73 | ALDH1A1 (0.36) | DUTALDH1A1POLBTSHRNPSR1 | |
| SCHEMBL850669 | 0.73 | ALDH1A1 (0.36) | DUTALDH1A1POLBTSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PTGER2 2036/4885PTGDR 890/4885PTGER3 330/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PTGER2 2036/4885PTGDR 890/4885PTGER3 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.